Crossmark

Lipoprotein(a)—It Is Risky, but What Do We Do About It?

Crossref DOI link: https://doi.org/10.1007/s12170-018-0592-7

Published Online: 2018-09-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Després, Audrey-Anne

Arsenault, Benoit J.
License Information

Text and Data Mining valid from 2018-09-29
More Information

Article History

First Online: 29 September 2018

Compliance with Ethical Standards

:

: Audrey-Anne Després is supported by a master’s training award from the <i>Fonds de recherche du Québec: Santé</i> (FRQS) and Canadian Institutes of Health Research and declares no conflicts of interest. Benoit Arsenault holds a junior scholar award from the FRQS and has received research funding from the Canadian Institutes of Health Research (FRN155226 and FRN149068), Pfizer, Merck and Ionis Pharmaceuticals.

: This article does not contain any studies with human or animal subjects performed by any of the authors.